| scholarly article | Q13442814 |
| P50 | author | Jean-Nicolas Vauthey | Q43369878 |
| P2093 | author name string | Jun Zhang | |
| Qiang Li | |||
| Asif Rashid | |||
| Liwei Wang | |||
| Zhenggang Zhu | |||
| Douglas B Evans | |||
| Keping Xie | |||
| James C Yao | |||
| Zhiliang Jia | |||
| P2860 | cites work | Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm | Q54116665 |
| Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. | Q54661904 | ||
| Pancreatic involvement in von Hippel–Lindau disease | Q62929393 | ||
| Expression of growth factor peptides and their receptors in neuroendocrine tumors of the digestive system | Q70463715 | ||
| Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours | Q72555370 | ||
| Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in gastrointestinal carcinoids | Q73132291 | ||
| Loss of heterozygosity at 11q13: analysis of pituitary tumors, lung carcinoids, lipomas, and other uncommon tumors in subjects with familial multiple endocrine neoplasia type 1 | Q73320115 | ||
| von Hippel-Lindau Disease | Q73979850 | ||
| Expression of vascular endothelial growth factor in digestive neuroendocrine tumours | Q74447035 | ||
| Genomic imbalances in the progression of endocrine pancreatic tumors | Q77361239 | ||
| Sp1- and Sp3-mediated Transcriptional Regulation of the Fibroblast Growth Factor Receptor 1 Gene in Chicken Skeletal Muscle Cells | Q77387620 | ||
| Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas | Q81609310 | ||
| Neuroendocrine cells along the digestive tract express neuropilin-2. | Q33950202 | ||
| Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood | Q34503083 | ||
| Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms | Q35745261 | ||
| Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma | Q35747496 | ||
| Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis | Q35753186 | ||
| Transcriptional anti-angiogenesis therapy of human pancreatic cancer | Q36413517 | ||
| Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression | Q36615803 | ||
| Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription | Q38291028 | ||
| The retinoblastoma gene product RB stimulates Sp1-mediated transcription by liberating Sp1 from a negative regulator | Q38306731 | ||
| Serum responsive gene expression mediated by Sp1. | Q38331118 | ||
| Cell-growth regulation of the hamster dihydrofolate reductase gene promoter by transcription factor Sp1. | Q38341788 | ||
| Sp1 and Sp3 transcription factors synergistically regulate HGF receptor gene expression in kidney | Q38359975 | ||
| Molecular alterations to human chromosome 3p loci in neuroendocrine lung tumors | Q38470995 | ||
| The von Hippel-Lindau Tumor Suppressor Gene Product Interacts with Sp1 To Repress Vascular Endothelial Growth Factor Promoter Activity | Q40023447 | ||
| Sp1 and NF-Y are necessary and sufficient for growth-dependent regulation of the hamster thymidine kinase promoter | Q40923019 | ||
| Identification and characterization of the putative retinoblastoma control element of the rat insulin-like growth factor binding protein-2 gene | Q40950925 | ||
| p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts | Q41026405 | ||
| Expression of the SRF gene occurs through a Ras/Sp/SRF-mediated-mechanism in response to serum growth signals | Q42807393 | ||
| Two distal Sp1-binding cis-elements regulate fibroblast growth factor receptor 1 (FGFR1) gene expression in myoblasts | Q43638486 | ||
| Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carcinoid tumors | Q46513918 | ||
| Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer | Q47290101 | ||
| Putative Control of Angiogenesis in Hemangioblastomas by the von Hippel-Lindau Tumor Suppressor Gene | Q48593082 | ||
| Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis | Q52952533 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| P304 | page(s) | 1478-1486 | |
| P577 | publication date | 2007-04-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors | |
| P478 | volume | 109 |
| Q37097257 | A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics |
| Q90425759 | A Systematic Review of Technical Parameters for MR of the Small Bowel in non-IBD Conditions over the Last Ten Years |
| Q37131421 | A phase II study of axitinib in advanced neuroendocrine tumors |
| Q37640526 | A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors |
| Q38406861 | Adenosine A2A and A2B receptor expression in neuroendocrine tumours: potential targets for therapy |
| Q27000397 | Advances in small bowel neuroendocrine neoplasia |
| Q37771118 | Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs). |
| Q33985773 | An analysis of trends and growth factor receptor expression of GI carcinoid tumors |
| Q37459597 | An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes |
| Q38005887 | Angiogenesis in Neuroendocrine Tumors: Therapeutic Applications |
| Q34487201 | Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors |
| Q39156308 | Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs? |
| Q37815624 | Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas |
| Q60960580 | Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib |
| Q50093655 | CT perfusion in normal liver and liver metastases from neuroendocrine tumors treated with targeted antivascular agents |
| Q46476659 | Chapter 6. Mouse models to investigate anti-cancer effects of VEGF inhibitors |
| Q26823035 | Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook |
| Q47128709 | Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy |
| Q43011998 | Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer |
| Q43121154 | Contemporary methods of therapy and follow-up of neuroendocrine tumours of the gastrointestinal tract and the pancreas. |
| Q38088366 | Current status and future prospects for anti-angiogenic therapies in cancer. |
| Q30488738 | Development and characterization of a novel in vivo model of carcinoid syndrome |
| Q57165714 | E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors |
| Q36901312 | Effect of Tumor Microenvironment on Tumor VEGF During Anti-VEGF Treatment: Systems Biology Predictions |
| Q37255846 | Emerging therapies and latest development in the treatment of unresectable pancreatic neuroendocrine tumors: an update for clinicians |
| Q37792813 | Endothelial contractile cytoskeleton and microvascular permeability |
| Q37356468 | Expression of livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma |
| Q26822011 | From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors |
| Q38010424 | Gastroenteropancreatic Neuroendocrine Tumors: Update on Therapeutics |
| Q90702187 | Histopathological, immunohistochemical, genetic and molecular markers of neuroendocrine neoplasms |
| Q35900751 | Immunohistochemical basis for adjuvant anti-angiogenic targeted therapy for renal carcinoid: initial case report |
| Q55536886 | Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms. |
| Q37839783 | Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors |
| Q93140756 | Isatin inhibits the invasion of human neuroblastoma SH‑SY5Y cells, based on microarray analysis |
| Q34157801 | KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors |
| Q35622038 | Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation |
| Q37777111 | Liver transplantation for non-hepatocellular carcinoma malignancy: Indications, limitations, and analysis of the current literature |
| Q38103116 | Management of Pancreatic Neuroendocrine Tumors |
| Q50227317 | Management of pulmonary neuroendocrine tumors |
| Q36994231 | Medical treatment of gastrinomas |
| Q37535022 | Molecular mechanisms of endothelial hyperpermeability: implications in inflammation |
| Q38331666 | Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors |
| Q36790050 | New Pharmacologic Therapies for Gastroenteropancreatic Neuroendocrine Tumors |
| Q26827785 | New Strategies for Advanced Neuroendocrine Tumors in the Era of Targeted Therapy |
| Q38010093 | New targeted agents in gastroenteropancreatic neuroendocrine tumors |
| Q37811564 | Novel Anticancer Agents in Clinical Trials for Well-Differentiated Neuroendocrine Tumors |
| Q37936908 | Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors. |
| Q57801663 | PDGFRα expression as a novel therapeutic marker in well-differentiated neuroendocrine tumors |
| Q38082596 | PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors |
| Q40091307 | Pancreatic neuroendocrine neoplasms: Correlation between MR features and pathological tumor grades |
| Q37995947 | Pancreatic neuroendocrine tumors: A comprehensive review |
| Q38372459 | Pancreatic neuroendocrine tumors: a review. |
| Q86061058 | Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors |
| Q38099390 | Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors |
| Q39224445 | Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. |
| Q39127234 | Pim-3 promotes the growth of human pancreatic cancer in the orthotopic nude mouse model through vascular endothelium growth factor |
| Q33597254 | Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas |
| Q37875054 | Potential Synergies for Combined Targeted Therapy in the Treatment of Neuroendocrine Cancer |
| Q38008839 | Radionuclide therapy via SSTR: future aspects from experimental animal studies |
| Q33885295 | Regulation of embryonic kidney branching morphogenesis and glomerular development by KISS1 receptor (Gpr54) through NFAT2- and Sp1-mediated Bmp7 expression. |
| Q38010658 | Relevance of angiogenesis in neuroendocrine tumors |
| Q37922650 | Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours |
| Q37282982 | Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis. |
| Q92823569 | Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms |
| Q35669138 | Safety and efficacy of everolimus in adult patients with neuroendocrine tumors |
| Q44694816 | Second primary malignancies in patients with neuroendocrine tumors |
| Q39952447 | Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential |
| Q38527936 | Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives. |
| Q38079854 | Systemic Therapy for Advanced Pancreatic Neuroendocrine Tumors |
| Q45797561 | Targeted therapies, prognostic and predictive factors in endocrine oncology |
| Q42728790 | Targeting mTOR pathway: A new concept in cancer therapy |
| Q26852089 | Targeting the mTOR signaling pathway in neuroendocrine tumors |
| Q42613248 | The involvement of PDGF/VEGF related factor in regulation of immune and neuroendocrine in Chinese mitten crab Eriocheir sinensis |
| Q37838801 | Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. |
| Q38858270 | Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms |
| Q38003074 | Translation of Molecular Pathways into Clinical Trials of Neuroendocrine Tumors |
| Q42379480 | Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors |
| Q43097453 | Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives |
| Q37025143 | Update on management of midgut neuroendocrine tumors |
| Q38879904 | Update on medical treatment of small intestinal neuroendocrine tumors |
| Q34453043 | Update on pancreatic neuroendocrine tumors |
| Q38250467 | Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations. |
| Q38266022 | Vascular endothelial growth factor trap-eye and trap technology: Aflibercept from bench to bedside |
Search more.